Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance and Corporate Update, and Host Conference Call
Get Alerts CORT Hot Sheet
Join SI Premium – FREE
MENLO PARK, CA -- (Marketwired) -- 01/21/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2015 financial results and provide 2016 revenue guidance and a corporate update on January 28, 2016. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode will be 4156 8920.
A replay will be available through February 11, 2016 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode will be 4156 8920.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym, a first generation cortisol modulator, is the company's first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer and has a portfolio of other proprietary selective GR antagonists that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its portfolio of selective cortisol modulators.
CONTACT: Charles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 Email Contact www.corcept.com
Source: Corcept Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corcept Therapeutics (CORT) Reports Positive Results From Open-Label Portion of Phase 3 GRACE Trial
- First Bancorp. (FBNC) Misses Q1 EPS by 2c
- Amerant Bancorp Inc. (AMTB) Misses Q1 EPS by 5c
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!